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Background: Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disease characterized by the
loss of motoneurons (MNs) in the spinal cord, brainstem and motor cortex, causing progressive paralysis and death.
Nowadays, there is no effective therapy and most patients die 2–5 years after diagnosis. Sigma-1R is a transmembrane
protein highly expressed in the CNS and specially enriched in MNs. Mutations on the Sigma-1R leading to frontotemporal
lobar degeneration-ALS were recently described in human patients. We previously reported the therapeutic role of the
selective sigma-1R agonist 2-(4-morpholi-nethyl)1-phenylcyclohexanecarboxylate (PRE-084) in SOD1G93A ALS mice, that
promoted spinal MN preservation and extended animal survival by controlling NMDA receptor calcium influx. Resveratrol
(RSV, trans-3,4′,5-trihydroxystilbene) is a natural polyphenol with promising neuroprotective effects. We recently found
that RSV administration to SOD1G93A mice preserves spinal MN function and increases mice survival. These beneficial
effects were associated to activation of Sirtuin 1 (Sirt1) and AMP-activated protein kinase (AMPK) pathways, leading to
the modulation of autophagy and an increase of mitochondrial biogenesis. The main goal of this work was to assess the
effect of combined RSV and PRE-084 administration in SOD1G93A ALS mice.
Methods: We determined the locomotor performance of the animals by rotarod test and evaluated spinal motoneuron
function using electrophysiological tests.
Results: RSV plus PRE-084 treatment from 8 weeks of age significantly improved locomotor performance and spinal MN
function, accompanied by a significant reduction of MN degeneration and an extension of mice lifespan. In agreement
with our previous findings, there was an induction of PKC-specific phosphorylation of the NMDA-NR1 subunit and an
increased expression and activation of Sirt1 and AMPK in the ventral spinal cord of treated SOD1G93A animals.
Conclusions: Although combined PRE and RSV treatment significantly ameliorated SOD1G93A mice, it did not show a
synergistic effect compared to RSV-only and PRE-084-only treated groups.
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Amyotrophic lateral sclerosis (ALS) is an adult onset
neurodegenerative disease characterized by the loss of
motoneurons (MN) in the spinal cord, brainstem and
motor cortex. It clinically manifests by progressive weak-
ness, muscle atrophy and paralysis [1,2]. The majority of
ALS cases are sporadic with unknown etiology but 10%
of them are inherited forms, linked to genetic mutations.
Mutations in the gene encoding for the enzyme Cu/Zn
superoxide dismutase 1 (SOD1) are observed in about
20% of the familial cases of ALS [3]. The transgenic
mouse that over-expresses the human mutated form of
the SOD1 gene with a glycine to alanine conversion at
the 93rd codon is the most studied model [4-6] and re-
capitulates the main features of both sporadic and famil-
ial ALS forms [5]. SOD1 protein alterations have also
been reported in sporadic ALS patients [7].
The sigma-1 receptor (sigma-1R) is an endoplasmic
reticulum (ER) transmembrane protein [8] highly expressed
in spinal MNs [9-11], and specially enriched in postsynaptic
sites of C-terminals [12]. Sigma-1R participates in several
cellular processes including neuritogenesis, ionic channels
conductance, calcium homeostasis and microglial activity
[13-16]. It has been implicated in diverse neuropathologies,
such as depression, schizophrenia and Alzheimer’s disease
[17]. A novel mutation of the sigma-1R has been recently
described in patients affected by juvenile ALS [18].
Sigma-1R agonists have demonstrated to promote pro-
tective effects reducing glutamate-mediated cell death
[19,20] or modulating inflammatory reaction following
stroke in rats [21]. Indeed, we have previously reported
the therapeutic role of the selective sigma-1R agonist
2-(4-morpholi-nethyl)1-phenylcyclohexanecarboxylate
(PRE-084) in SOD1G93A ALS mice, that promoted
spinal MN preservation and extended animal survival
by controlling NMDA receptor calcium influx [22].
Resveratrol (RSV, 3,5,4’-trihydroxy-trans-stilbene) is a
polyphenol naturally present in grapes and red wine that
has been reported to exert neuroprotective effects on
neurodegenerative disease models of Alzheimer’s disease
[23] and Parkinson’s disease [24], and in traumatic [25]
and ischemic injuries to the CNS [26]. Previous studies
showed protective effects after RSV administration on
in vitro ALS models [27,28]. We recently found that RSV
administration to SOD1G93A mice preserves spinal MN
function and increases their survival. These beneficial ef-
fects were associated to activation of Sirtuin 1 (Sirt1) and
AMP-activated protein kinase (AMPK) pathways, modula-
tion of autophagy and an increase of mitochondrial biogen-
esis [29-32].
The pathophysiology of ALS is complex, with several
processes contributing to MN death, including glutam-
ate excitotoxicity, oxidative stress, protein misfolding,
mitochondrial defects, impaired axonal transport andinflammation [33,34]. In this context, it is likely that
combined therapies targeting several pathophysio-
logical mechanisms could lead to stronger effects and
better functional outcomes, potentially resulting in
successful clinical translation. Thus, the main goal of
this study is to assess if the combination of PRE-084
and RSV treatments may have synergistic effects in the
SOD1G93A ALS mice.
Material and methods
Transgenic mice and drug administration
Transgenic mice with the G93A human SOD1 mutation
(B6SJL-Tg [SOD1-G93A]1Gur) were obtained from the
Jackson Laboratory (Bar Harbor, ME, USA), and main-
tained at the Animal Service of the Universidad de
Zaragoza. Hemizygotes B6SJL SOD1G93A males were
obtained by crossing with B6SJL females from the
CBATEG (Bellaterra, Spain). The offspring was identi-
fied by PCR amplification of DNA extracted from the
tail tissue. Mice were kept in standard conditions of
temperature (22 ± 2°C) and a 12:12 light:dark cycle with
access to food and water ad libitum. All experimental pro-
cedures were approved by the Ethics Committee of the
Universitat Autònoma de Barcelona, where the animal ex-
periments were performed.
Animals were evaluated at 8 weeks (prior to starting
treatments) by rotarod and electrophysiological tests to
obtain baseline values. Animals were distributed, accord-
ing to their progenitors, weight and electrophysiological
baseline values, in balanced experimental groups. A
RSV-enriched diet [23] was given to groups of treated
mice from 8 weeks of age. It has been previously dem-
onstrated that RSV does not affect food intake of the
animals [35], thereby assuming a normal food intake of
4 g/animal/day, then RSV was given at a daily dose
of 160 mg/kg. PRE-084 (Tocris Bioscience, Ellisville,
MO), a Sigma-1R agonist, was dissolved in saline and
administered daily by single intraperitoneal injections
at 0.25 mg/kg. The experimental groups included in
the study are summarized in Table 1.
Nerve conduction tests
Motor nerve conduction tests were performed at 8 weeks
of age and then every two weeks until 16 weeks in all
the animals used in the study. The sciatic nerve was
stimulated percutaneously by means of single pulses of
0.02 ms duration (Grass S88) delivered through a pair of
needle electrodes placed at the sciatic notch. The com-
pound muscle action potential (CMAP, M wave) was re-
corded from the tibialis anterior (TA) and the plantar
(interossei) muscles with microneedle electrodes [36,37].
All potentials were amplified and displayed on a digital
oscilloscope (Tektronix 450S) at settings appropriate to
measure the amplitude from baseline to the maximal
Table 1 Experimental groups included in the study
Experimental group Gender n
Wild type Females 10
SOD1 untreated Females 23
SOD1 + PRE Females 18
SOD1 + RSV Females 23
SOD1 + PRE + RSV Females 21
Wild type Males 10
SOD1 untreated Males 10
SOD1 + PRE Males 17
SOD1 + RSV Males 12
SOD1 + PRE + RSV Males 10
SOD1: SOD1G93A mice; PRE: PRE-084 (0.25 mg/kg i.p.); RSV: resveratrol
(160 mg/kg, via diet).
Mancuso et al. Orphanet Journal of Rare Diseases 2014, 9:78 Page 3 of 11
http://www.ojrd.com/content/9/1/78negative peak. To ensure reproducibility, the recording nee-
dles were placed under microscope to secure the same
placement on all animals guided by anatomical landmarks.
During the tests, mouse body temperature was kept con-
stant by means of a thermostated-controlled heating pad.
Locomotion tests and clinical disease onset
The rotarod test was performed to evaluate motor co-
ordination, strength and balance [38,39] in all the ani-
mals used in the study (Table 1). Mice were trained
three times a week on the rod rotating at 14 rpm, and
then tested from 8 to 16 weeks of age, with an arbitrary
maximum time of maintenance in the rotating rod of
180 s. Clinical disease onset was defined as the first day
when an animal was not able to complete the 180 sec-
onds on the rotating rod.
Survival
The mice were inspected daily until the standard end
point or death. It was considered that animals reached
the end point of the disease when they were unable to
right themselves in 30s when placed on their side.
Histology
At 16 weeks of age 4–5 mice of each group were trans-
cardially perfused with 4% paraformaldehyde in PBS and
the lumbar segment of the spinal cord was harvested,
post-fixed for 24 h, and cryopreserved in 30% sucrose.
Transverse 40 μm thick sections were serially cut with a
cryotome (Leica) between L2-L5 segmental levels. For
each segment, each section of a series of 10 was col-
lected sequentially on separate gelatin-coated slides or
free-floating in Olmos medium.
One slide of each animal was rehydrated for 1 min
and stained for 2 h with an acidified solution of 3.1 mM
cresyl violet. Then, the slides were washed in distilled
water for 1 min, dehydrated and mounted with DPX(Fluka). MNs counts were made for neuronal soma
present in the lateral part of lamina IX of the ventral horn
in the spinal cord sections and following strict size and
morphological criteria: only MNs with diameters larger
than 20 μm, polygonal shape and prominent nucleoli were
counted. The number of MNs present in both ventral
horns was counted in four serial sections of each L4 and
L5 segments [36,40], where motor nuclei innervating TA
and plantar muscles are located [41].
Another series of sections was blocked with PBS-Triton-
FBS and incubated overnight at 4°C with rabbit primary
antibody against ionized calcium binding adaptor molecule
1 (Iba1, 1:1000, Wako). After several washes, sections were
incubated for 1 hour at room temperature with Alexa 594-
conjugated secondary antibody (1:200; Life Science). For
co-localizations, spinal MNs were labeled with 500/525-
Neurotrace fluorescent Nissl staining (1:200, Life Science).
To quantify microglial immunoreactivity, microphoto-
graphs of the ventral horn grey matter were taken at × 400
and, after defining the threshold for background correction,
the integrated density of Iba1 labeling was measured using
ImageJ software. The integrated density represents the area
above the threshold for the mean density minus the
background.
Protein extraction and western blot
For protein extraction, another subsets of mice (4–5 of
each experimental group) were anesthetized and decapi-
tated at 16 weeks of age. The lumbar spinal cord was re-
moved and divided into quarters to isolate the ventral
quadrants. One of them was prepared for protein extrac-
tion and homogenized in modified RIPA buffer (50 mM
Tris–HCl pH 7.5, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.2% SDS, 100 mM NaCl, 1 mM EDTA) adding
10 μl/ml of Protease Inhibitor cocktail (Sigma) and
PhosphoSTOP phosphatase inhibitor cocktail (Roche).
After clearance, protein concentration was measured by
Lowry assay (Bio-Rad Dc protein assay).
To perform western blots, 20–30 μg of protein of
each sample were loaded in SDS-poliacrylamide gels.
The transfer buffer was 25 mM trizma-base, 192 mM
glycine, 20% (v/v) methanol, pH 8.4. The membranes
were blocked with 5% BSA in TBS plus 0.1% Tween-20
for 1 hour, and then incubated with primary antibodies
at 4°C overnight. The primary antibodies used were:
anti-GAPDH (MAB374, Millipore, 1:20000), anti-Sirt1
(ab50517, Abcam, 1:1000), anti-p53 (#2524, Cell Signaling,
1:500), anti-acetyl p53 (L382) (06–758, Millipore, 1:500),
anti-AMPK (#2532, Cell Signaling, 1:1000), anti-pAMPK
(#2531, Cell Signaling, 1:1000), anti-NMDAR1 (AB9864,
Millipore, 1:500) and anti-phospho NR1 (S896) (ABN88,
Millipore, 1:500). Horseradish peroxidase–coupled second-
ary antibody (1:5000, Vector) incubation was performed for
60 min at room temperature. The membranes were
Mancuso et al. Orphanet Journal of Rare Diseases 2014, 9:78 Page 4 of 11
http://www.ojrd.com/content/9/1/78visualized by enhanced chemiluminiscence method and the
images were collected and analyzed with a Gene Genome
apparatus using Gene Snap and Gene Tools software
(Syngene, Cambridge, UK), respectively.
Statistical analysis
Data are expressed as mean ± SEM. Electrophysiological
and locomotion test results were statistically analyzed using
repeated measurements and one-way ANOVA, applying
Turkey post-hoc test when necessary. Histological data
were analyzed using Mann–Whitney U test. Onset and sur-
vival data were analyzed using the Mantel-Cox test.
Results
Combined resveratrol and PRE-084 reduces locomotor
impairments and delays clinical disease onset in
SOD1G93A mice
We assessed locomotor performance with the rotarod test
[38,39]. Rotarod performance was significantly higher in
both female and male PRE + RSV treated mice than in con-
trol SOD1G93A mice (Figure 1). Furthermore, the combined
treatment significantly improved motor outcome of female
animals with respect to single RSV or PRE-084 mice at 15
and 16 weeks of age. However, in male mice PRE + RSV
did not produce additional benefits compared to singleFigure 1 PRE + RSV administration improves locomotor performance and
significant improvement in PRE + RSV treated animals compared to untreated li
had better performance at advanced stages than RSV and PRE-084 alone treate
untreated; #p < 0.05 vs. PRE-084 and @p < 0.05 vs. RSV treated SOD1G93A
PRE + RSV combination significantly delayed by 2 weeks the signs of distreatments. Regarding clinical disease onset, PRE + RSV
combination significantly delayed the first locomotor signs
compared to untreated SOD1G93A mice, but it not repre-
sented an improvement in comparison to single treated
groups (Figure 1).
Combined resveratrol and PRE-084 preserves spinal
motoneuron function in SOD1G93A mice
Lower MN dysfunction is one the main clinical signs of
ALS pathology both in animal models [36,41] and human
patients [1]. We assessed the functional state of spinal MN
by evaluating the amplitude of plantar and TA CMAPs. As
previously reported [36] there was a progressive decline in
CMAP amplitudes in both muscles along disease progres-
sion in SOD1G93A untreated mice. The results revealed that
PRE + RSV administration significantly preserves spinal
MN function compared to SOD1G93A untreated animals,
although it did not promote a better outcome than sepa-
rated RSV and PRE-084 treatments (Figure 2).
Combined resveratrol and PRE-084 extends survival of
SOD1G93A mice
RSV and PRE-084 combined administration from 8 weeks
of age significantly extended both female (12.9%) and male
(8.7%) lifespan compared to SOD1G93A untreated micedelays disease onset in SOD1G93A mice. (A) Rotarod test showed
ttermates. Female but not male SOD1G93A mice treated with PRE + RSV
d mice. Values are expressed as mean ± SEM. **p < 0.01, ***p < 0.001 vs.
mice. (B) Clinical onset analysis (Mantel-Cox test) revealed that
ease onset both in female and male SOD1G93A mice.
Figure 2 PRE + RSV treatment preserves lower motoneuron function. Electrophysiological tests performed in (A) female and (B) male
SOD1G93A mice revealed significant preservation of compound muscle action potentials (CMAP) amplitude in treated groups. Values are mean ±
SEM. *p < 0.05, **p < 0.01 PRE-084 vs. untreated; α p < 0.05, αα p < 0.01 PRE + RSV vs. untreated; ββ p < 0.01 RSV vs. untreated.
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prolonged mice survival with respect to PRE-084 (Mantel-
Cox test, p < 0.01) but not to RSV only treated SOD1G93A
mice (Figure 3).
Combined resveratrol and PRE-084 administration reduces
spinal motoneuron degeneration and reduces microglial
reactivity in SOD1G93A mice
Spinal MN preservation was assessed by evaluating the
number of Nissl stained MN cell bodies in the ventralFigure 3 PRE + RSV administration significantly extended SOD1G93A m
increased animals survival compared to PRE-084-only treated group (Mantehorns of lumbar L4-L5 spinal segments in 16 weeks old
SOD1G93A mice. Figure 4 shows representative images of
Nissl stained anterior horns to illustrate the differences
between experimental groups. MN counts of female
and male animals were pooled since there were no
significant differences between genders. PRE-084 and RSV
co-administration from 8 weeks of age significantly in-
creased the number of preserved MNs in SOD1G93A mice.
PRE + RSV treated mice had 33.3 ± 1.74 MNs (65.4% vs.
wild type) per section whereas SOD1G93A untreatedice survival (Mantel-Cox test, p < 0.001). PRE + RSV treatment also
l-Cox test, p < 0.05).
Figure 4 PRE + RSV administration significantly preserves spinal motoneurons from degeneration. Representative images of L4 spinal cord of
(A) wild type, (B) SOD1G93A untreated and (C) PRE + RSV SOD1G93A treated mice. Scale bar, 500 μm. (D) L4-L5 spinal cord motoneuron counts
revealed significant neuroprotection exerted by PRE + RSV co-administration compared to untreated SOD1G93A but not to RSV-only or
PRE-084-only treatments. Dashed line respresent the mean number of motoneurons per section of wild type mice. Values are mean ± SEM. ***p < 0.05 vs.
wild type, ### p < 0.05 vs. untreated SOD1G93A mice.
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a two-fold increase in surviving MNs. However, the
combinatory treatment did not represent improve-
ment in terms of neuronal preservation compared
to single RSV or PRE-084 administered animals
(Figure 4).Figure 5 PRE + RSV treatment significantly reduced Iba-1 immunoreactiv
of L4-L5 spinal cord of wild type, untreated SOD1 (SOD1c), and PRE, RSV and PR
compared to wild type values. Values are mean ± SEM. **p < 0.01 vs. SOD1c.We assessed the microglia reactivity as a measure of the
inflammatory state of the lumbar spinal cord. PRE + RSV
administration from 8 weeks of age significantly reduced
the microglial immunoreactivity in lamina IX of L4-L5
spinal cord segments. However, similar improvement was
observed with single PRE or RSV treatments (Figure 5).ity in L4-L5 spinal cord lamina IX. (A) Representative microphotographs
E + RSV treated groups. (B) Percentage increase of Iba-1 immunoreactivity
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AMPK activation, and promotes specific PKC-depended
phosphorylation of NMDA-NR1 subunits
We have previously shown that RSV treatment induced
an increased expression and activation of Sirt1 and
AMPK and a consequent modulation of autophagy and
mitochondrial biogenesis [32]. On the other hand, PRE-
084 administration leads to specific PKC-dependent
NMDA-NR1 subunit phosphorylation that may protect
MN from degeneration by reducing NMDA calcium
currents and thus preventing excitotoxicity [14,22,42].
Therefore, we further analyzed whether RSV and PRE-
084 co-administration similarly promotes the activation
of the same downstream cellular pathways or there was
any interference between drugs.
To assess RSV effects in the combinatory treated
SOD1G93A mice we first analyzed Sirt1 levels andFigure 6 Western blot analysis on the ventral lumbar spinal cord of anim
in SOD1G93A spinal motoneurons after PRE + RSV treatment. (B) Evaluation of S
deacetylation and thus, increased activity of Sirt1 in SOD1G93A mice treated wit
evidenced by an increased pAMPK/AMPK ratio. (D) Increased Ser896 PKC-spec
RSV. Values are mean ± SEM, *p < 0.05 vs. wild type, #p < 0.05 vs. untreated SODactivation in the ventral part of the lumbar spinal
cord by western blot analysis. Results revealed a pro-
nounced increase in Sirt1 expression after PRE + RSV
co-administration (Figure 6A). To check whether this
augmented expression was translated into an enhanced
function we analyzed the acetylation state of one the
most important Sirt1 targets, p53. We found a signifi-
cant reduction of acetyl-p53 proportion indicating that
Sirt1 was also over-activated (Figure 6B). Secondly, we
assessed the activation of AMPK by evaluating active
phospho-AMPK fraction. Results showed a marked
increase in the pAMPK/AMPK ratio after PRE + RSV
co-administration (Figure 6C). These changes were
similar to those previously reported after treatment
with RSV alone [32].
On the other hand, we evaluated the molecular effects
of PRE-084 by analyzing the phosphorylation state of aals co-administered with PRE + RSV. (A) Increased sirtuin 1 expression
irt1 activity by measuring the acetylation levels of p53 revealed significant
h PRE + RSV. (C) Enhanced AMPK activation after PRE + RSV treatment,
ific phosphorylation in NMDA-NR1subunits of animals treated with PRE +
1G93A mice.
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Western blot results showed increased Ser896 phosphoryl-
ation of the NMDA-NR1 subunit in the animals adminis-
tered with PRE + RSV (Figure 6D).
Discussion
The main goal of this study was to assess the effect of a
novel therapeutic approach combining a Sigma-1R agon-
ist, PRE-084, and RSV in the SOD1G93A mouse model
of ALS, since separate administration of the two com-
pounds had resulted in significant improvement of dis-
ease progression and survival of these mice [22,32]. Our
results indicate that co-administration of PRE-084 and
RSV from 8 weeks of age significantly preserved spinal
MNs function and reduced MN degeneration together
with a reduction of microglial immunoreactivity in the
lumbar spinal cord. This effect was accompanied by im-
provement in the locomotor performance and significant
extension of the animals survival. Western blot analyses
revealed that, as we previously described, PRE-084 in-
duced PKC-specific phosphorylation of Ser896 of the
NMDA-NR1 subunit, whereas RSV increased the ex-
pression and activation of Sirt1 and AMPK in the ventral
part of the lumbar spinal cord of SOD1G93A mice. Unfortu-
nately, the combinatory therapy did not represent a clear
improvement compared to RSV-only or PRE-084-only
treated animals.
Mechanisms of neuroprotection and possible overlapping
effects
As we previously described, PRE-084 promotes potent
neuroprotective effects to MNs both in vitro after exci-
totoxic insults [43], and in vivo after spinal root avulsion
[11] and in the SOD1G93A mouse model accompanied by
a significant extension of animals survival [22]. Calcium
dysregulation and excitotoxicity are two pathophysiological
mechanisms contributing to ALS pathology [44,45]. In fact,
spinal ALS-vulnerable MNs have an endogenous calcium
buffering capacity 5–6 times lower than that found in ALS-
resistant MNs, increasing their susceptibility to excitotoxic
insults [46]. NMDA receptor plays an important role dur-
ing excitotoxicity [45] and Sigma-1R agonists have been
shown to suppress calcium influx to the cells by modulating
NMDA receptor through PKC activation. Consistent with
our previous observations that PRE-084 administration
promotes PKC-specific NMDA-NR1 subunit phos-
phorylation [22], we have found that PRE + RSV com-
bined treatment also increased Ser896 phosphorylation
of the NDMA-NR1 subunit in the ventral part of the
spinal cord. Interestingly, increased NMDA-NR1 phos-
phorylation was only present in the treated group,
suggesting that the treatment is activating compensa-
tory protective pathways rather than counteracting a
pre-existent pathological event. Although it has beendemonstrated that Sigma-1R physically interacts with
NMDA-NR1 subunits [47], it has been also reported that
Sigma-1R agonists can modulate ionic flow through cal-
cium, sodium and potassium channels, thus modifying cell
excitability properties [14,48,49]. In fact, recent findings by
Mavlyutov et al. [50] indicate that the lack of Sigma-1R is
detrimental in SOD1G93A mice, probably because it acts by
reducing the excitability of spinal MNs. Moreover, Sigma-
1R is found associated to ER chaperones (such as BiP)
and plays a role in clearance of misfolded proteins by
the ERAD response [51,52]. Sigma-1R is enriched in
the so-called mitochondrial-associated ER membrane
(MAM) and its activation can also modulate mito-
chondrial metabolism [8,53].
It has been reported that RSV promotes protective ef-
fects both in neurodegenerative and traumatic injury
models, including Alzheimer’s disease and accelerated
aging [23,28,54], multiple sclerosis [55,56], Huntington’s
disease [57,58], Parkinson’s disease [24,59], and reducing
peripheral axonal degeneration [60] or promoting func-
tional improvements after spinal cord injury [25]. We
have recently found that RSV administration significantly
delays clinical symptoms onset, improves spinal MNs
function and survival, and extends SOD1G93A mice life-
span. We also determined that the therapeutic effect was
mediated by the increased expression and activation of
both Sirt1 and AMPK, leading to normalization of the
autophagic flux and enhanced mitochondrial biogenesis
[32]. Although there is some controversy about the exact
molecular mechanisms underlying RSV effect, it has
been established that Sirt1 or AMPK activation are up-
stream of pathways that participate in several cellular
processes, including inflammation [61-64], autophagy
[32] and mitochondrial function [29,54]. Consistent with
our previous findings, PRE + RSV treated animals also
presented higher expression and activation of both Sirt1
and AMPK compared to SOD1G93A untreated mice. As
we previously commented regarding increased NMDA-
NR1 phosphorylation, Sirt1 and AMPK overactivation
was only present in the treated group, suggesting that
the treatment activates protective pathways rather than
counteracts a pre-existent pathological condition. This
fact may increase the interest of these treatments since
the potentiation of endogenous protective mechanisms
can be translated to other non-SOD1 ALS situations.
Although the absence of summative effect in the PRE +
RSV treated group may be due to an insufficient dose of
any of the compounds, a possible overlapping in the path-
ways activated by both compounds may underlie the lack
of synergy. As above mentioned, RSV protective effect
is likely related to normalization of the autophagic flux
and increased mitochondrial biogenesis [32]. Although
PRE-084 main therapeutic effects have been consid-
ered associated to modulation of calcium influx and
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response to misfolded protein accumulation [8,52]
and the modulation of mitochondrial metabolism [53].
Considering this action, RSV effects on autophagy and
mitochondrial biogenesis may mask those of PRE-084
administration thus explaining the lack of summative
effect of the combined treatment. Alternatively, both
compounds may exert opposite effects on some path-
ways. For example, it has been reported that Sigma-1R
stabilize IRE1α and increase cell survival through tran-
scriptional activity of X Box binding Protein 1 (XBP1)
which in turn regulates genes responsible for protein
folding and degradation during the Unfolded Protein
Response (UPR) [51]. In contrast, RSV has been shown to
suppress the transcriptional activity of XBP1 through Sirt1
[65], therefore promoting an opposite action that could
contribute to the lack of synergistic effect of the combin-
atory treatment assayed.
Another explanation for the lack of summative effect
of the combined treatment lies in the pathology state of
the animals in the moment we began the drug adminis-
tration. SOD1G93A mice at 8 weeks of age present 25-
30% loss of CMAP amplitude in proximal muscles (TA
and gastrocnemius) [36,66], due to early neuromuscular
junction retraction and motor axons degeneration [41].
Thus, although MN cell bodies in the anterior spinal
cord are intact, up 30% of them are already under a de-
generative process that may be irreversible. Since our
treatment is focused on the preservation of remaining
functional MNs, it is likely that we are acting on the still
functioning population of MNs and thus, the maximum
effect that can be reached would be limited.
Does the SOD1G93A mouse model present a limited
therapeutic capacity?
An alterative explanation for the lack of summative ef-
fect after combining PRE-084 and RSV could be that the
SOD1G93A mouse model has a limit in terms of MN
function and survival that cannot be overpassed by
therapeutic interventions. To address this possibility, we
made a review of successful preclinical trials using both
single and combinatorial treatments in SOD1G93A mice.
Additional file 1: Table S1 shows a summary of the ther-
apies performed and the percentage of increased survival
compared to untreated mice. It is worth noting that no
replication of the positive results was achieved for sev-
eral of the drugs initially reported to provide efficacy
when re-tested using a careful study design [67]. Up to
our knowledge and without considering those works
showing negative or null results, only 4 of 48 studies
reported an extension of survival longer than 25% with
just a few showing synergistic effect after combinatory
approaches. Although deeper analyses must be performed,
such observations may reflect an endogenous limitation forthe therapeutical benefits that can be achieved using the
SOD1G93A mouse model.
Conclusions
The main goal of the present work was to assess the thera-
peutic potential of a combinatory strategy using RSV and
PRE-084 in the SOD1G93A mouse model of ALS. Our re-
sults revealed that RSV and PRE-084 co-administration
significantly improved MN functional preservation and
neuroprotection, accompanied by an improvement of the
locomotor performance and survival extension. However,
this effect was not comparatively better than that achieved
by administration of RSV alone.
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